Critical Care
Interventional
Mechanical Circulatory Support
Canadian Association of Interventional Cardiology (CAIC)
Canadian Cardiovascular Critical Care Society (CANCARE)
Canadian Cardiac Transplant Network (CCTN)
Canadian Heart Failure Society (CHFS)
Trainee
Rafael Alonso-Gonzalez, MD, MSc
ACHD Cardiologist
Peter Munk Cardiac Centre
University of Toronto
Filio Billia, MD, PhD
Clinician-Scientist
University Health Network (UHN)
Susanna Mak, MD PhD
Associate Professor of Medicine
University of Toronto
Michael Tsang, MD
Interventional Cardiologist
McMaster University
McMaster
Sean Van Diepen, MD, FRCPC
Associate Professor
University of Alberta
University of Alberta
Faizan Amin, MD
Associate Professor
CCTN
McMaster University
Mia Bertic, MD
Cardiologist and Cardiac Intensivist
Cancare
Anique Ducharme, MD, MSc, FCCS, FACCC (she/her/hers)
Cardiologist
Montreal Heart Institute
University of Montreal
Derek So, MD, FRCPC (he/him/his)
Dr.
CCS, CAIC
University of Ottawa Heart Institute
Barry Burstein, MD
CARDIOLOGIST
CCS, CANCARE
University of Toronto
Erin Rayner-Hartley, MD
Cardiology and Critical Care Medicine
Royal Columbian Hospital
University of British Columbia
Faizan Amin, MD
Associate Professor
CCTN
McMaster University
Anique Ducharme, MD, MSc, FCCS, FACCC (she/her/hers)
Cardiologist
Montreal Heart Institute
University of Montreal
Yoan Lamarche, MD, MSc
Cardiac surgeon and Intensivist
Montreal Heart Institute
Montreal Heart Institute
Dave Nagpal, MD
Cardiac Surgery / Critical Care Medicine
CCS, CSCS, CANCARE, CCTN
Western University
Gurmeet Singh, MD, MSc, FRCSC, FCCS
Associate Clinical Professor
University of Alberta
CANCARE, CSCS
Michael Tsang, MD
Interventional Cardiologist
McMaster University
McMaster
Workshop Description: Cardiogenic Shock remains a condition with unacceptably high in-hospital mortality. Recently there has been increasing interest in the use temporary mechanical circulatory support (t-MCS) for a certain subset of acute myocardial infarction cardiogenic shock (AMI-CS) using the using the percutaneous microaxial flow pump (mAFP) since the DanGer Shock trial was published. It demonstrated a survival advantage in mAFP use in a specific subset of AMI-CS due to primarily left ventricular pump failure in the absence of prolonged cardiac arrest.
This raises key practical clinical questions of how to best select patients and apply t-MCS optimally to be aligned with the evidence to translate trial data to clinical benefit. This symposium is intended for those who wish to elevate their approach in patient selection and application of recent trial data to real-world cases in Cardiogenic Shock.